890808 | 22:0 Trehalose

D-(+)-trehalose 6,6'-dibehenate


Powder

Size SKU Packaging Price
25mg 890808P-25mg 890808P-25mg $1,085.00
5mg 890808P-5mg 890808P-5mg $271.20
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}

22:0 Trehalose

22:0 Trehalose

D-(+)-trehalose 6,6'-dibehenate

Incorporation of the glycolipid trehalose 6,6'-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets.

Hygroscopic
No
Light Sensitive
No
Molecular Formula
C56H106O13
Percent Composition
C 68.12%, H 10.82%, O 21.06%
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
66758-35-8
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
987.433
Exact Mass
986.763
Synonyms
TDB
6,6'-didocosanoyl-α,α'-trehalose

Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, Jing Y, Zhang Z, Yue T, Zhou L, Fan X. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother. 2015;11(6):1456-64. doi: 10.1080/21645515.2015.1037057. PMID: 25905680; PMCID: PMC4514263.

PubMed ID: 25905680

Rose F, Wern JE, Ingvarsson PT, van de Weert M, Andersen P, Follmann F, Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release. 2015 Jul 28;210:48-57. doi: 10.1016/j.jconrel.2015.05.004. Epub 2015 May 6. PMID: 25957906.

PubMed ID: 25957906

Derrick SC, Yabe I, Morris S, Cowley S. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice. Clin Vaccine Immunol. 2016 Jul 5;23(7):638-47. doi: 10.1128/CVI.00232-16. PMID: 27226281; PMCID: PMC4933783.

PubMed ID: 27226281

Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017 Mar 7;35(10):1395-1402. doi: 10.1016/j.vaccine.2017.01.079. Epub 2017 Feb 9. PMID: 28190740.

PubMed ID: 28190740

Hansen M, Peltier J, Killy B, Amin B, Bodendorfer B, Härtlova A, Uebel S, Bosmann M, Hofmann J, Büttner C, Ekici AB, Kuttke M, Franzyk H, Foged C, Beer-Hammer S, Schabbauer G, Trost M, Lang R. Macrophage phosphoproteome analysis reveals MINCLE-dependent and -independent mycobacterial cord factor signaling. Mol Cell Proteomics. 2019 Jan 11. pii: mcp.RA118.000929. doi: 10.1074/mcp.RA118.000929. [Epub ahead of print]

PubMed ID: 30635358

Fomsgaard, A., Karlsson, I., Gram, G., Schou, C., Tang, S., Bang, P., Kromann, I., Andersen, P., Andreasen, L.V. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine. 29:7067-74.

PubMed ID: 21767590

Nordly, P., Agger, E.M., Andersen, P., Nielsen, H.M., Foged, C. (2011) Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res. 28:553-62.

PubMed ID: 21042837

Gram, G.J., Karlsson, I., Agger, E.M., Andersen, P., Fomsgaard, A. (2009) A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One. 4:e6950.

PubMed ID: 19759892

Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E.M., Andersen, P. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718:22-31.

PubMed ID: 16321607